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Abstract
Background: Much of chronic disease is managed in primary care and chronic kidney disease (CKD) is a recent
addition. We are conducting a cluster randomised study of quality improvement interventions in CKD (QICKD) -
Clinical Trials Registration: ISRCTN56023731. CKD registers have a lower than expected prevalence and an initial
focus group study suggested variable levels of confidence in managing CKD.
Our objective is to compare practitioner confidence and achievement of quality indicators for CKD with
hypertension and diabetes.
Method: We validated a new questionnaire to test confidence. We compared confidence with achievement of
pay-for-performance indicators (P4P) and implementation of evidence-based guidance. We achieved a 74% (148/
201) response rate.
Results: 87% (n = 128) of respondents are confident in managing hypertension (HT) compared with 59% (n = 87)
in managing HT in CKD (HT+CKD); and with 61% (n = 90) in HT, CKD and diabetes (CKD+HT+DM).
85.2% (P4P) and 62.5% (National targets) of patients with hypertension are at target; in patients with HT and CKD
65.1% and 53.3%; in patients with HT, CKD and DM 67.8% and 29.6%.
Confidence in managing proteinuria in CKD is low (42%, n = 62). 87% of respondents knew BP treatment
thresholds in CKD, but only 53% when proteinuria is factored in. Male GPs, younger (< 35 yrs), and older (> 54 yrs)
clinicians are more confident than females and 35 to 54 year olds in managing CKD.
84% of patients with hypertension treated with angiotensin modulating drugs achieve achieved P4P targets
compared to 67% of patients with CKD.
Conclusions: Practitioners are less likely to achieve management targets where their confidence is low.
Keywords: Renal Insufficiency, Chronic, Primary Care, Blood pressure, Family Practice, Quality of Healthcare, Protei-
nuria, Medical Records systems, computerised, Reimbursement, incentives
Background
The management of cardiovascular disease including
hypertension and diabetes is well established in primary
care [1-3] and chronic kidney disease (CKD) is a rela-
tively recent addition [4,5]. Computerisation of primary
care records and explicit national guidance supported by
pay for performance (P4P) targets have resulted in a
rapid improvement in chronic disease management in
primary care [6-9]. In CKD, guidance prioritises the
control of systolic blood pressure in patients with pro-
teinuria and or diabetes and recommends the use of
angiotensin modulating drugs for achieving control
[10-12].
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CKD is a new priority for primary care and little was
known about how to improve quality in CKD [13].
Patients with CKD can be readily identified using a sim-
ple formula to estimate glomerular filtration rate
(eGFR); a diagnosis is generally made when eGFR is
under 60 ml/min/1.73 m2 on at least two occasions
three months apart. People with CKD have a higher
mortality and morbidity principally due to cardiovascu-
lar disease [4]. Hypertension and diabetes were included
in P4P since its inception in 2004. CKD was added in
2006 with performance indicators for: creating a disease
register, measuring and controlling BP and proteinuria,
and treating high risk patients with angiotensin convert-
ing enzyme inhibitors [14]. However, the prevalence of
CKD reported when it was introduced as an indicator in
2006 was only half of that expected from epidemiologi-
cal studies, suggesting under-ascertainment [15]. We
carried out a diagnostic analysis to explore the factors
limiting the achievement of quality improvement [16].
This showed that primary care professionals had gaps in
their knowledge, highly variable views about this condi-
tion and lacked confidence in explaining and managing
the condition [17].
We carried out this questionnaire study to assess pri-
mary care clinician confidence in the management of
CKD and to explore whether confidence may be asso-
ciated with the quality of care.
Methods
Subjects
The subjects of this research are practitioners working
in 30 practices drawn from the 127 practices in the
Quality Improvement in Chronic Kidney Disease trial
(QICKD Clinical Trials Registration: ISRCTN56023731).
At the time of this study we were conducting a cluster
randomised trial (CRT) of quality improvement inter-
ventions in CKD [18] which includes conducting a pro-
cess evaluation to explore the reasons why the trial may,
or may not succeed [19]. The CRT has three arms:
“Audit based education” (feedback of performance com-
pared with peers in an educational context) [20];
“Guidelines and prompts” (postal reminders about man-
agement of CKD and copies of NICE guidance [15]);
and usual practice. The study has 25 practices per arm
to provide sufficient power to detect a change in systolic
BP, our primary outcome measure, between the arms.
The process evaluation involves six practices which par-
ticipate in an in-depth evaluation involving focus
groups, and an additional 10 practices per arm which
form a “Questionnaire group” in order to explore the
impact of the interventions on confidence in the man-
agement of CKD. The evaluation practices are excluded
from the final analysis of the CRT to avoid the possibi-
lity of contamination.
Participating practices
We randomly allocated 10 from each study arm as con-
fidence questionnaire evaluation practices (nested study
practices). Although randomly allocated the practices in
this nested study differ in age profile from the rest of
the QICKD trial and the UK national population. The
trial population is very close to the national population
in terms of its age-sex distribution [21]. The nested
study practices represented 14.9% of the study sample
population (138,774/930,997) and their practice popula-
tions were 1.5 years younger than those in the non-
questionnaire practices (mean age 37.0 years, SEM
0.046, compared with 38.5 SEM 0.27; t-test p < 0.001).
There was no significant difference in male: female ratio
between questionnaire and non-questionnaire practices
(Pearson Chi square p = 0.660) (Figure 1). The crude
prevalence of CKD in these practices was 5.4%. The
age-standardised prevalence of CKD was higher than
that of non-questionnaire practices (6.3% vs. 5.3%, OR
1.19: 95% CI 1.19-1.22, p < 0.01).
Distribution of the questionnaires and reminders
We sent a survey questionnaire to 30 practices (201
individual clinicians in total) and collected responses in
the three rounds (Figure 2). After the initial postal dis-
tribution three rounds of reminders were conducted.
Each round involved a telephone reminder to the parti-
cipant by a researcher to prompt completion by posting
a hard copy or to allow the participant to email a
scanned copy to a central administrator. Email remin-
ders were also sent at the same time as the phone calls.
The telephone reminder was carried out in as unobtru-
sive a way as possible.
Response rate
We sent a survey questionnaire to 30 practices (201
individual clinicians in total) and collected responses in
the three rounds (Figure 2). At the end 148 question-
naires were returned (74% response rate) from 93% (28/
30) practices.
Developing a confidence questionnaire
The questionnaire development was carried out in four
stages, using an established method [22]. We developed
objectives based on our study using knowledge gained
from our systematic review [13] and diagnostic analysis
[17]. We elected to make comparisons between CKD
and other conditions commonly managed in primary
care. The objectives of our questionnaire were:
• To compare the confidence of practitioners in con-
trolling systolic BP in patients with CKD with that in
patients with hypertension alone. Improved control of
systolic BP is the primary outcome measure of the CRT
[18].
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• To compare confidence in managing proteinuria in
CKD with diabetes. Patients with CKD and proteinuria
are at high risk of adverse renal and cardiovascular out-
comes [10].
• To compare confidence levels in General Practi-
tioner (GP) partners, salaried GPs and nurses. Our sys-
tematic review indicated that successful initiatives in
CKD had often been non-doctor led [13].
A draft questionnaire was circulated among the inves-
tigators who brainstormed the current issues in CKD
management. This draft questionnaire was then piloted
on practitioners. This cycle was repeated on three occa-
sions. We conducted three focus groups (n = 7, 6, 8) to
refine the questionnaire using groups of general practi-
tioners, practice nurses and medical students to validate
the questionnaire. These focus groups were facilitated
by the principal author to this paper.
The validation process involved the practitioners com-
pleting the questionnaire and then marking a colleague’s
questionnaire while discussing the responses and high-
lighting potential ambiguities. The focus groups were
reviewed and evaluated using a field notebook and tran-
scriptions of tape recordings. A smaller group of GPs were
contacted via email (n = 3) to ensure adequate validity.
We elected to include a small number of key compe-
tence measures as we felt that we could not interpret
confidence entirely isolated from competence. These
focussed on knowledge of BP targets for treatment, inter-
vention levels of proteinuria and criteria for referral. The
questionnaire consisted of 24 confidence questions rated
1 to 5 (Additional File 1) and 6 knowledge questions.
The confidence questions used a Likert scale from 1 to 5,
where 1 is “Not confident at all” and 5 is “Very confident.”
Collecting routine clinical data
We collected anonymised routine clinical data from the
computerised medical record systems of the question-
naire practices to enable us to compare confidence with
achievement. We extracted the key variables associated
with the questionnaire or required to make compari-
sons: practice identifier, age and gender, BP, significant
proteinuria, CKD (strictly applying a standard for
chronicity), diabetes (again using strict diagnostic cri-
teria) [23] or hypertension. Data were processed using
an established method [24] and analysed in SPSS (Statis-
tical Package for Social Sciences, Version 16).
Analysis plan
Our analysis had four stages:
1. Comparing confidence levels and knowledge for dif-
ferent age, gender and type of practitioner, and compar-
ing confidence in management of CKD with that of
hypertension and diabetes. We judge a person who
scored 4 or 5 on the questionnaire to be “confident”
and one scoring 1, 2 or 3 to be “not-confident”.
2. Establishing BP control and proportion at target for
people with CKD, with and without significant protei-
nuria, diabetes and hypertension.
Figure 1 Age-sex profile of non-questionnaire practices (left) with questionnaire practices (right).
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3. A comparison of level of confidence and achieve-
ment of the blood pressure targets set out in national
evidence-based guidance [10] and P4P indicators [11].
To do this we calculated a mean confidence score based
on the responses from each practice and compared this
with the achievement of P4P indicators by that practice.
4. Investigating variation in practice response
Statistical analysis
We used a range of descriptive and inferential statistical
procedures to compare differences in the samples and
outcomes. Where appropriate, we report the percentages
and 95% confidence intervals (CI) to allow comparison
between subgroups. For categorical variables, we used
the Pearson Chi square test to detect differences
between sub-groups or associations between variables.
We performed this analysis in SPSS version 16.
Ethical Considerations
The study has been approved by the Oxford Research
Ethics committee and is a registered clinical trial
(ISRCTN56023731).
Results
The final response rate was 74%. After three rounds of
reminders we received 148 questionnaires from 201 pri-
mary care professionals from 93% (28/30) of the
practices.
We found that most participants, 86.5% (n = 128; 95%
CI: 80.1% to 91.1%) in our study are confident in mana-
ging hypertension whereas only 58.8% (n = 87; CI:
50.7% to 66.4%) are confident in the management of
hypertension in patients with CKD, and 60.8% (n = 90;
CI: 52.7% to 68.3%) are confident in managing hyperten-
sion in patients with CKD and diabetes (DM). Just
Questionnaire
N=201
Sent
RETURNED
N=44
21.9%
NOT RETURNED
N=157
1st REMINDER 1 month later
Email or phone call 
from researcher
and copies resent on request
RETURNED
N=38
CUMULATIVE=82
40.8%
2nd REMINDER 2 months later
Email and phone call 
from senior clinical researcher
and hard copies where requested
RETURNED
N=12
CUMULATIVE=94
46.8%
3rd REMINDER 1 month later
Email and phone call 
from researcher
and hard copies where requested
RETURNED
N=54
CUMULATIVE=148
73.65%
Figure 2 The scheme of distribution and collection of questionnaires.
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under half of the respondents, 49.3% (n = 73; CI: 41.4%
to 57.3%) are confident in achieving lowered blood pres-
sure in patients with CKD (Figure 3).
Importantly, confidence is especially low in the man-
agement of patients with CKD and significant protei-
nuria, who are at higher risk of adverse renal and
cardiovascular outcomes. 42.6% (n = 63; CI: 34.9% to
50.6%) of respondents lack confidence with identifying
significant proteinuria in patients with CKD and only
41.9% (n = 62; CI: 34.2% to 49.9%) are familiar with
using urine protein results to manage CKD. Practi-
tioners are more confident in identifying significant pro-
teinuria in patients with DM, 64.9% (n = 96; CI: 56.9%
to 72.1%), and more confident in using urine protein
results to manage DM, 47.3% (n = 70; CI: 39.4% to
55.3%) than in patients with CKD.
About a third of respondents lack confidence with using
ACE-I and/or ARB in patients with CKD, 33.8% (n = 50;
CI: 26.7% to 41.7%). 66.9% (n = 99; CI: 59.0% to 74.0%) of
respondents lack confidence with adding a loop diuretic
drug (e.g. furosemide) to patients with CKD already on
maximum dose of an ACE-I and/or ARB. 35.8% (n = 53;
CI: 28.5% to 43.8%) of respondents lack confidence in
using anti-hypertensives that are not in the angiotensin
modulating category in patients with CKD (Figure 4).
More male GPs reported feeling confident in the over-
all management of CKD than female GPs, but the differ-
ence is not statistically significant (61.5% vs. 50.9%,
Pearson Chi Square p = 0.242). Male GPs (salaried GPs
and partners) are more confident in managing hyperten-
sion in patients with CKD (76.9% vs. 54.5%, p = 0.01)
and in managing hypertension in patients with CKD
and DM (73.8% vs. 56.4%, p < 0.05) than female GPs.
Also male GPs are more confident with using an ACE-I
and/or ARB or other anti-hypertensive(s) in patients
with CKD (86.2% and 84.6% vs. 65.5% and 63.6%, p <
0.01) compared with their female counterparts.
When it comes to adding a loop diuretic drug (e.g.
furosemide) to patients with CKD already on maximum
dose of an ACE I and/or ARB, male GPs are approxi-
mately twice as confident as female GPs (50.8% vs.
25.5%, p = 0.005).
Confidence in the management of patients with CKD
was ranked by respondents’ age (Table 1). Younger clin-
icians (< 35 year old) are more confident in managing
hypertension than the 35-54 year old group (100.0% vs.
80.6%, p = 0.023). At the same time, more of the
younger (< 35 year old) and more of the older (55 and
older) practitioners are confident in the management of
hypertension in patients with CKD than the 35-54 year
old group (69.6%, 77.4% vs. 50.0%, p = 0.014). 73.9% of
the < 35 years old group but only 39.4% of 35-54 years
olds are confident in achieving lowered blood pressure
in patients with CKD (p = 0.004).
The younger group are significantly more confident than
the 35-54 year old group in interpreting eGFR to stage
CKD (87% vs. 61.7%, p = 0.02) and monitoring eGFR in
patients with CKD (87% vs. 61.7%, p = 0.033), and in mon-
itoring eGFR in CKD patient with DM (69.6% vs. 51.1%, p
= 0.01). Only about half of respondents in each group felt
confident in using urine protein results to manage DM
(47%, p = 0.034) and in CKD (41.9%, p = 0.3).
The > 54 year old group have the highest confidence,
compared to the 35-54 year old and < 35 year old
groups, in using referral guidelines to refer appropriate
patients with either both DM and CKD (83.9% vs. 52.2%
vs. 54.3% p = 0.01), or CKD alone (80.6% vs. 56.5% vs.
45.7% p = 0.03) to secondary care.
17.4% and 41.5% of respondents in the < 35 year old
group and the 35-54 year old group respectively are not
confident with using ACE-I and/or ARB in patients with
CKD. This difference was statistically significant (p =
0.03).
86.5% (n = 128) of practitioners were able to correctly
identify the P4P thresholds for blood pressure control in
patients with CKD without proteinuria compared with
53.4% (n = 79) of respondents when proteinuria is fac-
tored in.
Next we evaluated clinical outcomes in the manage-
ment of blood pressure. The mean systolic BP in the
86.50%
58.80% 60.80%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HT HT + CKD HT + CKD + DM
n= 128 87 90
Figure 3 Confidence in managing hypertension.
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98 95
49
29
50 53
99
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
ACE I and/or ARB ACE I and/or ARB in
CKD
Other anti-hypertensives
in CKD
Loop diuretic drug in CKD 
Confident Not confident
Figure 4 Confidence in using antihypertensive drugs.
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study population as a whole was 125 mmHg and in the
population without any cardiovascular (CVS) co-mor-
bidity was 122 mmHg.
Analysis of overall practice performance in BP man-
agement revealed poor BP control in patients with CKD
and low numbers of patients reaching BP goals (both
NICE targets and P4P payment thresholds, Table 2).
Only half of patients (53.3%) with CKD and hyperten-
sion have achieved the NICE target for blood pressure
management whereas this number was 62.5% for people
with hypertension without CKD. In patients with CKD
and diabetes this figure drops to 29.6%. Currently P4P
thresholds for BP are higher than NICE. 67.80% of
patients with CKD and DM meet P4P thresholds for BP
management.
Patients with CKD and both proteinuria and diabetes
are a high risk group in whom lowering systolic BP is
particularly important. There appears to be a lack of
confidence in treating these patients and this is rein-
forced by a low achievement of BP targets, with only
31.3% patients meeting at goal of 130 mmHg as recom-
mended by NICE.
70% of patients with HT received angiotensin modu-
lating drugs for blood pressure treatment (mean BP
achieved 138.6 mmHg). 61.4% of these patients meet
NICE targets and 84.2% meet P4P thresholds for BP
control.
79% of CKD patients (mean 136.3) received ACE-I or
ARB. However, in the same group, only 48.8% (NICE)
and 67.0% (P4P) of patients are at target for BP control.
Table 1 Confidence in managing CKD and DM in different age groups
Confidence 0-34 35-54 55+ p
N % N % N %
Managing hypertension 23 100.0% 75 80.6% 29 93.5% 0.02
Managing hypertension in patients with CKD 16 69.6% 47 50.0% 24 77.4% 0.01
Managing hypertension in patients with CKD with DM 15 65.2% 52 55.3% 23 74.2% 0.16
Achieving lowered blood pressure in patients with CKD 17 73.9% 37 39.4% 19 61.3% 0.00
Interpreting eGFR to stage CKD 20 87.0% 58 61.7% 25 80.6% 0.02
Monitoring eGFR in patients with CKD 20 87.0% 58 61.7% 24 77.4% 0.03
Monitoring eGFR in CKD patient with DM 16 69.6% 48 51.1% 25 80.6% 0.01
Using urine protein results to manage DM 15 65.2% 37 39.4% 18 58.1% 0.03
Using urine protein results to manage CKD 12 52.2% 35 37.2% 15 48.4% 0.31
Using ACE inhibitors and/or ARB 22 95.7% 71 75.5% 26 83.9% 0.08
Using ACE inhibitors and/or ARB in patients with CKD 19 82.6% 55 58.5% 24 77.4% 0.03
Using other anti-hypertensives in patients with CKD 18 78.3% 54 57.4% 23 74.2% 0.08
Adding a loop diuretic drug (e.g. furosemide) to patients with CKD already on maximum dose of an ACE I
and/or ARB
7 30.4% 26 27.7% 16 51.6% 0.05
Using referral guidelines to refer appropriate patients with DM to secondary care 12 52.2% 51 54.3% 26 83.9% 0.01
Using referral guidelines to refer appropriate patients with CKD to secondary care 13 56.5% 43 45.7% 25 80.6% 0.00
Overall management of patients with DM 15 65.2% 54 57.4% 26 83.9% 0.03
Overall management of patients with CKD 9 39.1% 44 46.8% 22 71.0% 0.03
Table 2 Confidence and achievements in BP management in patients with CKD and DM
Confidence % BP Mean Patients at NICE target Patients at P4P target
Managing HT 86.5% 138.07 8701 62.5% 11853 85.2%
Managing HT in patients with CKD 58.8% 137.43 2575 53.3% 3141 65.1%
Managing HT in CKD with DM 60.8% 136.26 420 29.6% 963 67.8%
Urine protein results to manage DM 47.3% 135.38 193 32.5% 467 78.6%
Urine protein results to manage CKD 41.9% 140.96 5 21.7% 16 69.6%
ACE-I and/or ARB in HT only 80.4% 138.6 5330 61.4% 7310 84.2%
ACE-I and/or ARB in CKD 66.2% 136.3 2796 48.8% 3841 67.0%
Assessing CVD risk scores in DM 71.6% 128.8 456 71.0% 516 80.4%
Assessing CVD risk scores in CKD 63.5% 129.7 232 73.9% 277 88.2%
Overall management of DM 64.2% 133.2 3556 46.4% 6377 83.2%
Overall management of CKD 50.7% 133.9 6262 56.4% 7932 71.4%
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Practitioner confidence is also low so far as treatment of
these conditions are concerned.
Practitioner confidence is lowest in managing the fol-
lowing groups; patient with CKD, with DM and protei-
nuria, and with CKD and proteinuria (58.1%, 47.3% and
41.9% respectively). CKD combined with DM or HT or
both produce higher confidence values than that of
CKD alone.
We compared individual practice responses to see if
outliers or practice variation might account for a differ-
ence in confidence levels. We found no difference
related to list size and similar results for the different
patient groups (Figure 5).
Discussion
Principal findings
Practitioners are less confident in managing CKD than
hypertension or diabetes. There is also a lack of confi-
dence in managing proteinuria, combined with a knowl-
edge gap in interpreting proteinuria test results.
Within the respondent group, salaried doctors, males,
older and younger doctors and GPs compared to nurses
were more confident in managing CKD. Clinicians are
least confident in managing individuals with CKD who
are at highest risk, i.e. those with proteinuria. Confi-
dence is lower in managing patients with proteinuria
and CKD than those patients with proteinuria and
diabetes.
The quality of care in CKD, measured by ascertain-
ment of standards in national guidance and for P4P is
lower where confidence is low. This is particularly
apparent in CKD and in people with CKD and diabetes.
Nearly all (> 80%) of people with hypertension taking
an angiotensin modulating drug achieve national quality
targets compared with two-thirds of people with CKD.
Implications for practice
Low practitioner confidence and knowledge gaps may be
reversed by educational interventions. The QICKD
study, using information (guidelines and prompts) and
education (audit based education) will inform whether
these interventions change confidence and ultimately
the quality of care. These interventions were chosen as
they represented two common initiatives used in pri-
mary care to improve care and thought to prompt
change in practice.
Interventions may need to be tailored to meet the
needs of different practitioner groups, as there are
marked differences between the groups of practi-
tioners. Nurses in particular should have specific train-
ing as this clinician group deliver much of the chronic
disease management in primary care and increasingly
chronic kidney disease management. One consequence
of P4P may be that practices improve quality up to the
standard required to achieve the indicator. The highest
risk patients, who may also be the most difficult to
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Figure 5 Salaried GP, GP Partner and Practice Nurse scores across practice list size.
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manage, may not be optimally treated. Incentives could
be tailored to reward achievement of NICE thresholds
for the highest risk patients, for example the use of
Local Enhanced Services in Primary Care Trusts in
England.
Comparison with the literature
Other studies have shown a knowledge gap in CKD
management [25,26] reinforcing the findings of our
own diagnostic analysis [17]. There are some pointers
from educational research and from other disease areas
that level of knowledge [27,28] and confidence is asso-
ciated with improved practice [29-32]; however most
of these articles are descriptive rather than conducted
in trials.
It may be premature to presume that the patterns of
practitioner confidence described in our study are gen-
eraliseable. One study of knowledge of CKD showed it
declined with increasing practitioner age [25]. Another,
in the field of dementia [31] suggested younger and
female GPs had greater knowledge and awareness;
whereas the exploration of discussing sexual difficulties
showed no gender difference [32].
Limitation of the method
There may be a number of sources of bias in this inves-
tigation. Firstly, the practices participating in the
QICKD study are volunteer practices who may not be
representative of the wider population. Secondly, we
have no information about the non-responders.
We can only look at comparing individual practi-
tioners’ responses with practice level outcome data. This
is because most practices allow patients to see a number
of doctors.
Call for future research
We need to determine the cost effectiveness of any edu-
cational intervention updating economic modelling
based on previous guidance [33]. Further studies which
provide educational or other interventions to people
who lack confidence in managing a condition should be
conducted to determine whether this improves the qual-
ity of care.
Conclusion
Practitioners are less confident in managing CKD than
hypertension or diabetes and are less likely to achieve
BP targets where confidence is low. Improving knowl-
edge and confidence may provide the key to improving
the quality of CKD management in primary care, espe-
cially for higher risk patients with diabetes and with
proteinuria.
Additional material
Additional file 1: Questionnaire: How confident are General
Practitioners & the Primary care team in managing Chronic Kidney
Disease (CKD).
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